Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Current Deferred Revenue (2018 - 2025)

China SXT Pharmaceuticals (SXTC) has 8 years of Current Deferred Revenue data on record, last reported at $58627.0 in Q1 2025.

  • For Q1 2025, Current Deferred Revenue fell 68.76% year-over-year to $58627.0; the TTM value through Mar 2025 reached $58627.0, down 68.76%, while the annual FY2025 figure was $58627.0, 68.76% down from the prior year.
  • Current Deferred Revenue reached $58627.0 in Q1 2025 per SXTC's latest filing, down from $187665.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $257449.0 in Q1 2021 and bottomed at $58627.0 in Q1 2025.
  • Average Current Deferred Revenue over 5 years is $149328.2, with a median of $165534.0 recorded in 2023.
  • Peak YoY movement for Current Deferred Revenue: plummeted 69.95% in 2022, then skyrocketed 113.96% in 2023.
  • A 5-year view of Current Deferred Revenue shows it stood at $257449.0 in 2021, then tumbled by 69.95% to $77366.0 in 2022, then skyrocketed by 113.96% to $165534.0 in 2023, then increased by 13.37% to $187665.0 in 2024, then plummeted by 68.76% to $58627.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $58627.0 in Q1 2025, $187665.0 in Q1 2024, and $165534.0 in Q1 2023.